EAM
ACHN

Eventide Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Eventide Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-850,000
Closed -$2.45M – 153
2017
Q4 		$2.45M Hold
850,000
– – 0.13% 104
2017
Q3 		$3.82M Hold
850,000
– – 0.22% 84
2017
Q2 		$3.9M Buy
850,000
+250,000
+42% +$1M 0.24% 79
2017
Q1 		$2.53M Buy
+600,000
New +$2.49M 0.17% 90

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Eventide Asset Management's ACHN Position: Q1 2018 in Review

Eventide Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 850,000 shares — an estimated $2.45M sold.

Eventide Asset Management first reported a position in ACHN in Q1 2017 and held it in 4 quarters. The position peaked at $3.9M in Q2 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Eventide Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Eventide Asset Management sold 850,000 Achillion Pharmaceuticals shares in Q1 2018, an estimated $2.45M.
  • Eventide Asset Management first reported a position in Achillion Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Eventide Asset Management's Achillion Pharmaceuticals position peaked at $3.9M in Q2 2017.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Eventide Asset Management's 13F filing for Q1 2018, filed 15 May 2018.